Paul Horstmeier - Health Catalyst Chief Officer
| HCAT Stock | USD 8.52 0.39 4.80% |
Insider
Paul Horstmeier is Chief Officer of Health Catalyst
| Age | 63 |
| Address | 10897 South River Front Parkway, South Jordan, UT, United States, 84095 |
| Phone | 801 708 6800 |
| Web | https://www.healthcatalyst.com |
Paul Horstmeier Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Horstmeier against Health Catalyst stock is an integral part of due diligence when investing in Health Catalyst. Paul Horstmeier insider activity provides valuable insight into whether Health Catalyst is net buyers or sellers over its current business cycle. Note, Health Catalyst insiders must abide by specific rules, including filing SEC forms every time they buy or sell Health Catalyst'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Horstmeier over six months ago Disposition of 50000 shares by Paul Horstmeier of Health Catalyst at 4.42 subject to Rule 16b-3 |
Health Catalyst Management Efficiency
The company has return on total asset (ROA) of (0.0526) % which means that it has lost $0.0526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2146) %, meaning that it created substantial loss on money invested by shareholders. Health Catalyst's management efficiency ratios could be used to measure how well Health Catalyst manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.22 in 2024. Total Current Liabilities is likely to drop to about 74.4 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 532.3 M in 2024Similar Executives
| Showing other executives | INSIDER Age | ||
| Bud JD | Simulations Plus | N/A | |
| Tom Penque | Definitive Healthcare Corp | N/A | |
| William Frederick | Simulations Plus | 60 | |
| Gregory MS | National Research Corp | N/A | |
| Robert JD | Definitive Healthcare Corp | 54 | |
| , PharmD | Certara | N/A | |
| Max Wygod | Forian Inc | 36 | |
| MS MS | Simulations Plus | 54 | |
| Andy Brailo | Premier | N/A | |
| Joseph Mirisola | Definitive Healthcare Corp | 40 | |
| William Feehery | Certara | 53 | |
| Jim MD | Privia Health Group | N/A | |
| Kaycee Kalpin | Premier | N/A | |
| Michael Vesey | Forian Inc | 62 | |
| Aammaad Shams | Evolent Health | 40 | |
| Tunde Sotunde | Evolent Health | N/A | |
| Kate Jensen | Definitive Healthcare Corp | 38 | |
| Tyson Murdock | HealthEquity | 53 | |
| Nicolette Sherman | Certara | 54 | |
| David Terrell | Forian Inc | N/A | |
| Craig Barbarosh | Evolent Health | 52 | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.0526 |
Health Catalyst Leadership Team
Elected by the shareholders, the Health Catalyst's board of directors comprises two types of representatives: Health Catalyst inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Health. The board's role is to monitor Health Catalyst's management team and ensure that shareholders' interests are well served. Health Catalyst's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Health Catalyst's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maxine Liu, Senior Interopability | ||
| Holly Rimmasch, Senior Officer | ||
| Kevin Freeman, Chief Officer | ||
| Paul Horstmeier, Chief Officer | ||
| Tarah Bryan, Chief Officer | ||
| Ryan Barry, Chief Services | ||
| Kyle Salyers, Chief Development | ||
| Adam Brown, Senior Analysis | ||
| Kevin Scharnhorst, Chief Officer | ||
| Jeffrey Selander, Senior International | ||
| Daniel LeSueur, Chief Officer | ||
| Jason Jones, Chief Platform | ||
| Benjamin Landry, General Board | ||
| Bryan Hunt, Senior Advisor | ||
| T Elbert, Chief VP | ||
| Linda Llewelyn, Chief Officer | ||
| Amanda Flanders, Senior Communications | ||
| Dave Ross, Chief Officer | ||
| Daniel Burton, CEO Director | ||
| Daniel Orenstein, Senior Advisor | ||
| Patrick Nelli, Advisor | ||
| Jason Alger, Chief Officer |
Health Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Health Catalyst a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.0526 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 471.77 M | ||||
| Shares Outstanding | 60.85 M | ||||
| Shares Owned By Insiders | 2.77 % | ||||
| Shares Owned By Institutions | 90.69 % | ||||
| Number Of Shares Shorted | 2.84 M | ||||
| Price To Earning | (2.62) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Health Stock Analysis
When running Health Catalyst's price analysis, check to measure Health Catalyst's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Health Catalyst is operating at the current time. Most of Health Catalyst's value examination focuses on studying past and present price action to predict the probability of Health Catalyst's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Health Catalyst's price. Additionally, you may evaluate how the addition of Health Catalyst to your portfolios can decrease your overall portfolio volatility.